



Title	Measuring non-polyaminated lipocalin-2 for cardiometabolic risk assessment
Author(s)	YANG, K; Deng, H; MAN, WC; SONG, E; Zhang, J; Luo, C; Cheung, BMY; Yuen, KY; Jensen, PS; Irmukhamedov, A; Elie, A.G.I.M; Vanhoutte, PMGR; Xu, A; De Mey, JGR; Wang, Y
Citation	ESC Heart Failure, 2017
Issued Date	2017
URL	http://hdl.handle.net/10722/242221
Rights	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Measuring non-polyaminated lipocalin-2 for cardiometabolic risk assessment

Kangmin Yang^{1,2}, Han-Bing Deng^{1,2†}, Andy W.C. Man^{1,2}, Erfei Song^{1,2}, Jialiang Zhang³, Cuiting Luo^{1,2}, Bernard M.Y. Cheung³, Kwok-Yung Yuen⁴, Pia Søndergaard Jensen⁵, Akhmadjon Irmukhamedov⁶, Atlanta G.I.M. Elie⁷, Paul M. Vanhoutte^{1,2}, Aimin Xu^{1,3}, Jo G.R. De Mey^{6,7} and Yu Wang^{1,2*}

¹State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; ²Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China; ³Department of Medicine, The University of Hong Kong, Hong Kong, China; ⁴Department of Microbiology, The University of Hong Kong, Hong Kong, China; ⁵Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark; ⁶Department of Cardiac, Thoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark; ⁷Department of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark

Abstract

Aims Lipocalin-2 is a pro-inflammatory molecule characterized by a highly diversified pattern of expression and structure–functional relationships. *In vivo*, this molecule exists as multiple variants due to post-translational modifications and/or protein–protein interactions. Lipocalin-2 is modified by polyamination, which enhances the clearance of this protein from the circulation and prevents its excessive accumulation in tissues. On the other hand, animal studies suggest that non-polyaminated lipocalin-2 (npLcn2) plays a causal role in the pathogenesis of obesity-associated medical complications. The present study examined the presence of npLcn2 in samples from healthy volunteers or patients with cardiac abnormalities and evaluated npLcn2 as a biomarker for cardiometabolic risk assessment.

Methods and results Immunoassays were developed to quantify npLcn2 in blood and urine samples collected from 100 volunteers (59 men and 41 women), or venous plasma and pericardial fluid samples obtained from 37 cardiothoracic surgery patients. In healthy volunteers, npLcn2 levels in serum are significantly higher in obese and overweight than in lean subjects. After adjustment for age, gender, smoking, and body mass index (BMI), serum npLcn2 levels are positively correlated with heart rate, circulating triglycerides, high-sensitivity C-reactive protein (hsCRP), and creatinine in plasma. The npLcn2 levels in urine are significantly increased in subjects with metabolic syndrome and positively correlated with BMI, heart rate, circulating triglycerides, and urinary aldosterone. In cardiothoracic surgery patients, the circulating concentrations of npLcn2 are higher (more than two-fold) than those of healthy volunteers and positively correlated with the accumulation of this protein in the pericardial fluid. Heart failure patients exhibit excessive expression and distribution of npLcn2 in mesothelial cells and adipocytes of the parietal pericardium, which are significantly correlated with the elevated plasma levels of npLcn2, total cholesterol, and creatinine.

Conclusions Quantitative and qualitative evaluation of npLcn2 in human biofluid samples and tissue samples can be applied for risk assessment of healthy individuals and disease management of patients with obesity-related cardiometabolic and renal complications.

Keywords Lipocalin-2; Cardio-renal metabolic syndrome; Polyamination; Biomarker

Received: 24 October 2016; Revised: 13 April 2017; Accepted: 4 May 2017

*Correspondence to: Yu Wang, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China. Tel: +852 3917 6864; Fax: +852 2817 0859. Email: yuwanghk@hku.hk

†Present address. Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.

Introduction

Lipocalin-2 (also known as neutrophil gelatinase-associated lipocalin, neu-related lipocalin, uterocalin, siderocalin, or

24p3) is an adipokine circulating in the bloodstream and belongs to the lipocalin family, which functions as transporters of lipophilic substances.^{1,2} Lipocalin-2 possesses unique bacteriostatic properties by sequestering enterobactin³ and is

implicated in cardiometabolic abnormalities associated with obesity, including hypertension, type 2 diabetes, renal injury, and heart failure.^{4–11} Circulating lipocalin-2 levels are augmented in obese human subjects and positively correlated with anthropometric metabolic variables including insulin resistance index, hyperlipidaemia, hyperglycaemia, and inflammation.¹¹ Mice without lipocalin-2 are protected against dietary or genetic obesity-induced endothelial dysfunction, hypertension, insulin resistance, and elevation of circulating lipid and glucose levels.^{4,9,10,12} Despite this information, the pathophysiological role of lipocalin-2 remains largely uncharacterized. In particular, there are disputes on the precise type of cells in which the protein is expressed under both physiological and pathological conditions.

Lipocalin-2 is post-translationally modified by polyamination, which promotes the clearance of this protein from the circulation.⁹ In animals fed with high-fat diet, circulating levels of non-polyaminated lipocalin-2 (npLcn2) are significantly increased and contribute to the development of obesity-associated pathologies.⁹ Although pharmacological interventions in mice suggest that treatment with npLcn2 causes vascular inflammation, endothelial dysfunction, and hypertension, there lacks evidence from human studies to support such a pathophysiological role in clinical settings. In the present study, the antibodies and immunoassays specifically recognizing npLcn2 were developed to analyse its expression in different human samples and association with various cardiometabolic risk factors.

Materials and methods

Human participants

The study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (reference number UW 14-044) and performed in accordance with the International Conference on Harmonisation's Guideline for Good Clinical Practice (ICH GCP) guidelines, local regulations, and Hospital Authority and the University policies to comply with the Declaration of Helsinki. One hundred volunteers including 59 men and 41 women were recruited from Hong Kong community inhabitants from October to December 2015. Informed written consent was obtained from all subjects prior to their participation in the study. Criteria of exclusion were pregnancy or lactation; alcohol intake within the past 24 h; long-term drug treatment or medications taken within 1 week prior to the study; and any known diagnoses of hypertension, diabetes, dyslipidaemia, anaemia, coronary heart disease, chronic obstructive pulmonary disease, asthma, hepatitis, primary hyperaldosteronism, renal dysfunction, and eczema. Anthropometric parameters [including age, body mass index (BMI), waist circumference, heart rate, and systolic

and diastolic arterial blood pressures] were assessed by standardized procedures. The healthy volunteer cohort included 37 lean (BMI < 23 kg/m²), 27 overweight (BMI = 23–24.9 kg/m²), and 36 obese (BMI ≥ 25 kg/m²) individuals, according to the Asia-Pacific guidelines of obesity classification.¹³ In addition, 37 patients who underwent elective coronary artery bypass grafting (26 subjects), valve replacement surgery (six subjects), or both (five subjects) were recruited at the Odense University Hospital for a study approved by the Medical Ethics Committee of the Region of Southern Denmark (S-20100044).¹⁴ The demographic and clinical characteristics of all study subjects are summarized in *Table 1*.

Laboratory analyses

After overnight (10–12 h) fasting, serum, plasma, and urine samples were collected between 8:00 a.m. and 10:00 a.m. for the Hong Kong participants. Plasma samples were collected from Danish participants the day before surgery. Pericardial fluid and biopsy from the parietal pericardium of the patients were collected during the elective coronary artery bypass grafting or cardiac valve replacement surgeries. Tissue biopsies were fixed in neutral-buffered formalin for 48 h. All biofluid samples were stored at –80°C. Fasting blood glucose was analysed using Accu-Chek Advantage II Glucometer (Roche Diagnostics, Mannheim, Germany). Triglycerides, total cholesterol (TC), high density lipoprotein (HDL), and low density lipoprotein (LDL) cholesterol levels in serum samples were analysed using respective LiquiColor test kits from Stanbio Laboratory (Boerne, TX, USA). Circulating lipid and haemoglobin A1c (HbA1c) levels in plasma collected from the Danish patients were measured at the Odense University Hospital.¹⁴

Immunoassays

Serum or plasma concentrations of adiponectin, lipocalin-2, high-sensitivity C-reactive protein (hsCRP), and fibroblast growth factor 21 (FGF21) were measured using in-house enzyme-linked immunosorbent assay (ELISA) kits (<http://www.pharma.hku.hk/swab/antibody/ELISA.php>) as described.^{15–22} Plasma and urinary creatinine were measured using a commercial kit according to the manufacturer's instructions (ABCAM, Cambridge, UK). The concentrations of haptoglobin and kidney injury molecule-1 (KIM-1) in urine samples were determined by ELISA kits purchased from Biovendor (Candler, NC, USA) and R&D Systems (Minneapolis, MN, USA), respectively. Aldosterone levels were determined in serum and urine samples using the DetectX Aldosterone Enzyme Immunoassay kit (Cayman Chemical, Ann Arbor, MI, USA). In brief, steroids were extracted from 60 µL of serum with ethyl acetate, dried, and dissolved in 140 µL assay buffer, whereas 28 µL urine samples were diluted five-fold with assay buffer. For measurement, 100 µL of serum

Table 1 Characteristics of the study subjects^a

Parameters	Hong Kong healthy volunteers	Danish patients
Age (years)	48 ± 7	69 ± 9
Current/former/never smokers	9/9/82	5/7/25
BMI (kg/m ²)	23.8 ± 2.7	28.7 ± 5.5
Waist circumference (cm)	82 ± 7	—
Heart rate	65 ± 8	—
SBP (mmHg)	117 ± 14	135 ± 21
DBP (mmHg)	74 ± 11	73 ± 13
FBG (mmol/L)	5.8 ± 0.7	—
Triglycerides (mmol/L)	1.7 ± 0.8	1.4 ± 0.6
TC (mmol/L)	5.4 ± 0.9	3.8 ± 0.9
HDL (mmol/L)	1.6 ± 0.2	1.1 ± 0.4
LDL (mmol/L)	3.5 ± 0.9	2.1 ± 0.9
Plasma creatinine (μmol/L)	52.5 ± 9.6	94.6 ± 30.1
Plasma hsCRP (mg/L)	2.1 (1.0–7.5)	3.9 (1.8–8.4)
Plasma FGF21 (ng/L)	81.7 (30.4–138.6)	134.2 (52.9–225.9)
Anti-hypertensive drugs	—	78.3%
Statins	—	56.7%
Anti-diabetic drugs	—	29.7%
Left ventricular ejection fraction	—	53 ± 8%

DBP, diastolic blood pressure; FBG, fasting blood glucose; FGF21, fibroblast growth factor 21.

^aData are shown as means ± SD or median (interquartile range) when not normally distributed.

extracts or urine dilutions was incubated with 50 μL solutions containing DetectX aldosterone conjugate and antibodies in coated 96 well plates overnight at 4°C. After washing with phosphate-buffered saline (PBS) and adding the substrates for 30 min, the reactions were terminated and the absorbance was read at 450 nm using a plate reader (BioTek Instruments Inc., Winooski, VT, USA).

Antibody production and validation

Wild-type human lipocalin-2 is polyaminated.⁹ Replacing the cysteine 87 residue by alanine (C87A) in human lipocalin-2 significantly reduces the amount of polyamines bound to the protein.⁹ C87A exhibits a longer plasma half-life than did wild-type human lipocalin-2 and induces vascular inflammation.⁹ Here, wild-type human lipocalin-2 and the C87A mutant were expressed as His-tagged recombinant proteins and purified as described.^{9,11} After the removal of endotoxin, the protein purity was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and mass spectrometry analysis. Polyclonal antibodies against human lipocalin-2 or C87A were produced as described.^{9,11} The two types of antibodies exhibited different affinities to purified human lipocalin-2 or C87A protein. The antibody against C87A could barely recognize wild-type human lipocalin-2 during immunoprecipitation (*Figure S1*). The antibodies were subsequently purified by affinity chromatography for testing in human urine samples. In brief, after removing the sediments by centrifugation at 2000 *g* for 5 min, 100 mL urine samples were concentrated to 1 mL using a centrifugal filter concentrator (Millipore® UFC900308 Amicon® Ultra-15 with 3000 Da nominal molecular weight limit). Fifteen microlitres of the concentrated urine samples was separated by SDS-PAGE, transferred to polyvinylidene difluoride

membranes, and incubated with antibodies against either human lipocalin-2 or C87A. The immune-complexes were detected with chemiluminescence reagents from GE Healthcare (Uppsala, Sweden). Both antibodies are able to detect lipocalin-2, however, with different patterns of migration and abundance (*Figure S2*). For immunoprecipitation, the concentrated urine samples containing 500 μg proteins were diluted in 500 μL PBS, pre-cleared with 50 μL protein A agarose beads slurry (Thermo Fisher Scientific, Waltham, MA, USA), and then incubated overnight with 2.5 μg of antibodies against either human lipocalin-2 or C87A at 4°C under gentle agitation. Samples were then incubated with 100 μL of 50% protein A agarose beads slurry at room temperature for 2 h under rotary agitation. After washing three times with PBS, the immune-complexes were eluted with SDS-PAGE loading buffer for western blotting to detect the amount of polyamines attached to the precipitated lipocalin-2 using a specific antibody against spermidine (ABCAM). Compared with the proteins precipitated by antibodies against wild-type human lipocalin-2, the protein precipitated by the antibodies against C87A contained a barely detectable amount of polyamines (*Figure S2B*). Thus, the two antibodies recognize polyaminated lipocalin-2 (pLcn2) and npLcn2, respectively.

Development of sandwich ELISA

The sandwich ELISA for measurement of human lipocalin-2 or pLcn2 has been reported.^{11,15,19} In addition, a sandwich ELISA for npLcn2 measurement was established using unlabeled and biotinylated C87A antibodies for coating and detection, respectively. Biotinylation was performed with a kit from Thermo Scientific™ Pierce™, and free biotin removed by dialysis. The microtitre plate was pre-coated with 100 μL

unlabeled antibodies (2 µg/mL) overnight at 4°C and then blocked with 100 µL of PBS containing 1% bovine serum albumin (BSA) and 0.05% Tween-20 for 2 h at room temperature. For measurement, 100 µL diluted (25-fold) serum or non-diluted urine, or recombinant protein standards was applied into each well of the coated ELISA plates for 1 h incubation at room temperature, followed by three washings and another hour of incubation with biotinylated antibodies. The bound immunocomplexes were detected with streptavidin-conjugated horseradish peroxidase and substrates. The reactions were stopped before measurement of the absorbance at 450 nm with a plate reader (BioTek Instruments Inc.). The inter-assay and intra-assay coefficients of variance were determined by measuring six plasma samples from healthy subjects in a total of five independent assays with duplicate determinations.

Immunohistochemistry

Formalin-fixed, paraffin-embedded tissue sections (5 µm of thickness) were preheated at 60°C, deparaffinized, hydrated, and then subjected for antigen retrieval in 0.01 M citrate buffer (pH 6.0). The endogenous peroxidase activity was quenched with 0.3% H₂O₂ for 15 min at room temperature. After blocking with 5% BSA in PBS for 30 min at room temperature, the tissue sections were incubated with anti-human lipocalin-2 (5 µg/mL in PBS containing 5% BSA) or anti-C87A (5 µg/mL in PBS containing 5% BSA) antibodies overnight at 4°C. Anti-rabbit secondary antibodies (1:1000, P0448; Dako, Glostrup, Denmark) were applied for 45 min at room temperature, followed by colorimetric detection with 3,3'-diaminobenzidine. All sections were counterstained with Mayer's haematoxylin prior to analysis under a microscope (BX51; Olympus, Tokyo, Japan) and with the Olympus cellSens Entry imaging software, version 1.7.

Targeted disruption of murine *Lcn2* gene

The flippase recognition target (FRT)-Neo-FRT-loxP (1898 bp) was inserted in intron 1 and the loxP site located downstream of exon 2 of *LCN2* (ENSMUSG00000026822, <http://www.ensembl.org/index.html>). Following selection, positive embryonic stem clones were introduced into C57BL/6 blastocysts to produce chimeric mice, which were cross-bred with C57BL/6J mice. The *Lcn2*-floxed mice were obtained and subsequently crossed with the *LysCre* B6.129P2-Lyz2tm1(*cre*) *Ifo*/J mice from Jackson Laboratory (Bar Harbor, ME, USA), which expressed a *Cre* recombinase from the lysozyme M-encoding locus. The myeloid lineage-specific lipocalin-2 knockout mice (*Lys*-LKO) were produced and maintained on a C57BL/6J background. Three sets of primers were used for genotyping. Primer 1 (forward 5'-AAATGCTTCTGTCCGTTTGC-3' and reverse

5'-CGGCATCAACGTTTTCTTTT-3') was used for amplifying a 128 bp fragment of the *Cre* recombinase sequence. Primer 2 (forward 5'-TGAATGAACTGCAGGACGAG-3' and reverse 5'-TGATGCTCTTCGTCCAGATCAT-3') and Primer 3 (forward 5'-GAGCGATCAGGTAGGACCCT-3' and reverse 5'-CCTGCCCGGA ACTGCAAGA-3') were used for amplifying a 319 bp fragment of the floxed *LCN2* and a 437 bp fragment of wild-type *LCN2*, respectively.

Neutrophil–mesothelial cell interactions

The human mesothelial cell line MeT-5A (ATCC® CRL-9444™) was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in M199 medium. The human primary mesothelial cells were purchased from Zen-Bio (Zen-Bio Inc., Research Triangle Park, NC, USA) and cultured in MSO-1 (Zen-Bio Inc.). After 48 h, the conditioned media were collected for neutrophil cell incubation. Neutrophils were harvested from lipocalin-2 general knockout mice.^{9,10} In brief, bone marrow cells were flushed out from femurs and tibias with Ca²⁺/Mg²⁺-free Hank's buffered saline solution supplemented with 20 mM Na-HEPES (pH 7.4). The cell suspension was filtered with a 70 µm cell strainer (Falcon #352350) and re-suspended for Percoll density gradient separations. After centrifuging at 1600 g for 30 min, neutrophils were collected between the layers of 78%, 69%, and 52% Percoll and incubated with the conditioned media for 4 h at 37°C prior to analyses.

Statistical analysis

All statistical calculations were performed with the IBM (Chicago, IL, USA) SPSS version 21.0 software. Data were expressed as means ± SD or medians with interquartile range, as appropriate. The Kolmogorov–Smirnov test was used to analyse the distribution of different variables. Natural logarithmic transformation was applied for data with non-normal distribution. The independent *t*-test was used for comparison of continuous variables between two groups. Partial Pearson correlations were used to establish the relationship between variables of interest, with adjustment for age and gender. A *P* value of less than 0.05 was used to indicate a significant difference in all statistical comparisons.

Results

Gender differences

The levels of pLcn2 and npLcn2 in serum and urine samples collected from the healthy volunteer cohort were analysed using in-house ELISA kits (Table 2). The average concentrations

of pLcn2 in serum were comparable with those in urine samples, whereas the average concentrations of serum npLcn2 were higher (more than 25-fold) than those of urine npLcn2. Consequently, the ratio pLcn2/npLcn2 was significantly lower in serum than in urine samples. Both pLcn2 and npLcn2 concentrations were significantly lower in serum samples of female participants than those of male subjects. However, pLcn2 and npLcn2 levels in urine samples from female subjects were higher (about five-fold and about two-fold, respectively) than those from male subjects (Table 2). The gender differences of pLcn2 and npLcn2 in serum and urine samples remained significant after adjustment for BMI, waist circumference, and smoking (data not shown). The pLcn2/npLcn2 ratios were not significantly different between men and women. There were no significant associations

between serum or urine concentrations of lipocalin-2 and age, for both pLcn2 ($P = 0.303$ and 0.875 , respectively) and npLcn2 ($P = 0.315$ and 0.555 , respectively). The 75th percentile cut-off for serum and urinary lipocalin-2 levels in the healthy volunteers were 121.4 and 106.0 ng/mL for pLcn2, and 125.8 and 9.1 ng/mL for npLcn2, respectively (Figure S3).

Obese subjects (27 men and 9 women) had significantly higher serum pLcn2 (121.5 vs. 57.8 ng/mL) and npLcn2 (124.2 vs. 67.6 ng/mL) levels than lean subjects (Figure 1A). The overweight subjects also showed significantly higher serum npLcn2 levels (89.6 ng/mL) than did lean subjects. According to the National Cholesterol Education Program criteria,²³ the subjects were grouped into those with zero, one, two, or three risk factors of metabolic syndrome. Urinary npLcn2 levels were

Table 2 Lipocalin-2 concentrations in samples collected from male and female subjects of Hong Kong healthy volunteer cohort^a


	Total cohort (n = 100)	Male (n = 59)	Female (n = 41)
Age (years)	—	48.2 ± 7.5	48.3 ± 7.2
BMI (kg/m ²)	—	24.7 ± 2.1*	22.7 ± 3.0
Waist circumference (cm)	—	84.9 ± 5.4*	77.7 ± 8.0
Serum pLcn2 (ng/mL)	69.8 (42.3–126.4)	85.9 (48.0–139.7)*	54.2 (33.7–79.1)
Serum npLcn2 (ng/mL)	93.8 (63.1–143.3)	102.6 (69.6–162.0)*	81.5 (54.2–105.1)
Serum pLcn2/npLcn2	0.81 (0.6–1.0)	0.86 (0.7–1.1)	0.76 (0.6–0.9)
Urine pLcn2 (ng/mL)	60.8 (20.7–164.1)	30.6 (16.3–78.0)*	161.0 (35.4–341.4)
Urine npLcn2 (ng/mL)	3.7 (1.7–8.1)	3.0 (1.6–5.0)*	6.5 (3.0–13.5)
Urine pLcn2/npLcn2	13.76 (10.7–21.4)	13.03 (10.6–20.8)	15.5 (11.8–22.6)

BMI, body mass index; pLcn2, polyaminated lipocalin-2; npLcn2, non-polyaminated lipocalin-2.

^aData are shown as means ± SD or median (interquartile range) values.

* $P < 0.05$ vs. female subjects.

Figure 1 Comparison of lipocalin-2 concentrations in serum and urine samples of Hong Kong healthy volunteer cohort. (A) The polyaminated lipocalin-2 (pLcn2; left) and non-polyaminated lipocalin-2 (npLcn2; right) levels of serum (top) or urine (bottom) samples were measured and compared among lean, overweight, and obese subjects as defined by the Asia-Pacific guidelines of obesity classification.¹³ (B) The pLcn2 (left) and npLcn2 (right) levels of serum (top) or urine (bottom) samples were measured and compared among subjects with zero, one, two, and three risk factors of metabolic syndrome. * $P < 0.05$ ($n = 13$ –37).



significantly increased in those with three risk factors (13 subjects, five men, and eight women) (Figure 1B).

Correlation analysis for samples from healthy volunteers

In samples from the healthy volunteer cohort, serum pLcn2 or npLcn2 levels were positively correlated with BMI, heart rate, diastolic blood pressure, triglycerides, plasma hsCRP, and creatinine but negatively correlated with circulating concentrations of adiponectin, independently of age, gender, and smoking (Table 3). After further adjustment for BMI, the

positive correlations between npLcn2 and heart rate, triglycerides, hsCRP, or creatinine remained significant. The serum pLcn2/npLcn2 ratios were negatively correlated with TC ($r = -0.299$, $P = 0.004$) or adiponectin ($r = -0.253$, $P = 0.015$), and positively correlated with hsCRP ($r = 0.338$, $P = 0.001$), independently of age, gender, smoking, and BMI.

The concentrations of pLcn2 ($P = 0.960$) or npLcn2 ($P = 0.312$) in the urine were not significantly correlated with those in serum samples. After adjustment for age, gender, and smoking, urinary npLcn2 levels were positively correlated with BMI, heart rate, and serum triglyceride concentrations (Table 4). The correlations between urinary lipocalin-2 levels and serum triglycerides remained significant after further

Table 3 Correlations between serum lipocalin-2 concentrations and study variables of Hong Kong healthy volunteer cohort

	Serum pLcn2 ^a				Serum npLcn2 ^a			
	<i>r</i> ^b	<i>r</i> ^c	<i>P</i> ^b	<i>P</i> ^c	<i>r</i> ^b	<i>r</i> ^c	<i>P</i> ^b	<i>P</i> ^c
BMI	0.362	—	<0.001	—	0.376	—	<0.001	—
Waist circumference	—	—	—	—	0.236	—	0.020	—
Heart rate	0.248	—	0.016	—	0.287	0.214	0.004	0.036
SBP	—	—	—	—	—	—	—	—
DBP	0.201	—	0.052	—	0.240	—	0.018	—
FBG	—	—	—	—	—	—	—	—
Triglycerides	0.289	0.211	0.005	0.042	0.354	0.283	<0.001	0.005
TC	—	—	—	—	—	—	—	—
HDL	—	—	—	—	—	—	—	—
LDL	—	—	—	—	—	—	—	—
FGF21	—	—	—	—	—	—	—	—
hsCRP	0.418	0.302	0.000	0.003	0.372	0.250	0.000	0.024
Plasma creatinine	0.221	—	0.029	—	0.269	0.244	0.008	0.017
Adiponectin ^a	-0.330	0.222	0.001	0.034	-0.297	—	0.003	—

BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; FGF21, fibroblast growth factor 21; hsCRP, high-sensitivity C-reactive protein; npLcn2, non-polyaminated lipocalin-2; pLcn2, polyaminated lipocalin-2; TC, total cholesterol.

^aLogarithmic transformed before analysis.

^bAdjusted for age, gender, and smoking.

^cAdjusted for age, gender, smoking, and BMI.

Table 4 Correlations between urinary lipocalin-2 concentrations and study variables of Hong Kong healthy volunteer cohort

	Urine pLcn2				Urine npLcn2			
	<i>r</i> ^a	<i>r</i> ^b	<i>P</i> ^a	<i>P</i> ^b	<i>r</i> ^a	<i>r</i> ^b	<i>P</i> ^a	<i>P</i> ^b
BMI	—	—	—	—	0.214	—	0.018	—
Waist circumference	0.202	0.191	0.029	0.037	—	—	—	—
Heart rate	—	—	—	—	0.167	—	0.051	—
SBP	—	—	—	—	—	—	—	—
DBP	0.175	—	0.050	—	—	—	—	—
FBG	—	—	—	—	—	—	—	—
Triglycerides	0.214	0.199	0.021	0.031	0.228	0.184	0.012	0.043
TC	—	—	—	—	—	—	—	—
HDL	—	—	—	—	—	—	—	—
LDL	—	—	—	—	—	—	—	—
Serum aldosterone	—	—	—	—	—	—	—	—
Urine aldosterone ^c	0.258	0.248	0.008	0.011	0.185	0.326	0.001	0.044
Urine KIM-1 [0.15 (0.02–0.47) ng/mL]	—	0.317	—	0.001	—	0.186	—	0.034
Urine haptoglobin [6.3 (6.2–17.9) ng/mL]	—	—	—	—	—	—	—	—
Urine creatinine [5.0 (2.5–12.2) mmol/L]	—	—	—	—	—	—	—	—

BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; KIM-1, kidney injury molecule-1; npLcn2, non-polyaminated lipocalin-2; pLcn2, polyaminated lipocalin-2; TC, total cholesterol.

^aAdjusted for age, gender, and smoking.

^bAdjusted for age, gender, smoking, and BMI.

^cLogarithmic transformed before analysis.

adjustment for BMI. Both pLcn2 and npLcn2 in urine were significantly correlated with KIM-1, a specific marker for kidney injury.²⁴ Urine samples contained a higher level [1009.9 (482.5–2013.6) pg/mL] of aldosterone than did serum samples [106.0 (77.7–131.3) pg/mL]. Aldosterone levels in the urine were positively correlated with waist circumference ($r = 0.275$, $P = 0.023$). The urinary pLcn2 ($r = 0.248$, $P = 0.011$) and npLcn2 ($r = 0.185$, $P = 0.044$) levels were positively correlated with the concentrations of aldosterone in the urine, independently of age, gender, smoking, and BMI (Table 4).

Correlation analysis for samples from cardiothoracic surgery patients

Among the 37 patients in the Danish cohort (31 male and six female subjects), most had been prescribed cholesterol-lowering, renin–angiotensin system inhibitory, anti-hypertensive, and anti-diabetic medications.¹⁴ When compared with those of the Hong Kong healthy volunteers, the plasma pLcn2/npLcn2 ratios were reduced more than four-fold, owing mainly to the increased npLcn2 levels (Table 5). Both pLcn2 and npLcn2 were present in the pericardial fluid samples of all patients, with a median ratio of 0.47 for pLcn2/npLcn2. The pLcn2 and npLcn2 levels in the pericardial fluid samples correlated significantly with those in the circulation (Table 5). Compared with those with left ventricular ejection fraction (LVEF) over 50%, patients with LVEF equal or below 50% showed a significant elevation of npLcn2 in both plasma and pericardial fluid samples (Table 6).

Based on National Cholesterol Education Program criteria,²³ eight patients of the Danish cohort with two or more components of metabolic syndrome had significantly higher concentrations of npLcn2 levels, in both the plasma (241.9±54.2 ng/mL) and pericardial fluid samples (56.3±25.4 ng/mL), than the 15 subjects exhibiting none of these components (180.8±35.6 and 37.0±9.6 ng/mL for plasma and pericardial fluid, respectively); the npLcn2 levels in other patients ($n = 14$) were 213.0±51.6 and 49.5±21.6 ng/mL, respectively (Figure 2). Positive associations were found between plasma levels of npLcn2 and hsCRP ($r = 0.359$, $P = 0.017$) or FGF21 ($r = 0.382$, $P = 0.017$). There were significant positive correlations of plasma creatinine levels with pLcn2 ($r = 0.404$, $P = 0.023$) or npLcn2 ($r = 0.630$, $P \leq 0.001$) in pericardial fluid samples.

The presence and distribution of pLcn2 and npLcn2 were analysed by immunohistochemical staining of the pericardial tissue biopsies (Figure S4). While both pLcn2 and npLcn2 were detected in cells (referred to as leucocytes) located within or close to blood or lymph vessels, their patterns of distribution were significantly different when comparing the staining images from adjacent sections. The number of leucocytes containing pLcn2 was significantly less than that

Table 5 Concentrations of lipocalin-2 in plasma and pericardial fluid samples of Danish patients^a

	Plasma			Pericardial fluid			Correlation between plasma and pericardial fluid	
	Total cohort	Male		Total cohort	Male		<i>r</i>	<i>P</i>
		Female	Female		Female	Female		
pLcn2	35.6 (28.4–46.7)	38.5 (29.9–51.9)	29.9 (24.7–63.0)	18.0 (14.0–26.7)	19.2 (12.9–28.7)	15.2 (14.0–35.5)	0.817	<0.001
npLcn2	207.5 (162.8–249.7)	209.3 (164.9–254.2)	191.3 (130.7–272.7)	36.5 (28.9–51.5)	37.4 (28.8–61.4)	36.5 (34.0–69.8)	0.442	0.010
pLcn2/npLcn2	0.19 (0.16–0.23)	0.20 (0.17–0.24)	0.20 (0.14–0.24)	0.47 (0.41–0.61)	0.47 (0.41–0.65)	0.43 (0.38–0.54)	0.028	0.876

npLcn2, non-polyaminated lipocalin-2; pLcn2, polyaminated lipocalin-2.

^aData are shown as median (interquartile range) values.

Table 6 Comparison of lipocalin-2 levels in plasma and pericardial fluid samples of Danish patients according to cardiac function as indicated by left ventricular ejection fraction^a

	LVEF > 50% (n = 27)	LVEF ≤ 50% (n = 10)	P
Plasma pLcn2	32.2 (24.4–40.4)	48.8 (33.3–67.4)	0.090
Plasma npLcn2	176.1 (138.9–219.2)	214.1 (181.6–280.9)	0.038
Fluid pLcn2	16.7 (13.5–24.0)	25.1 (14.2–39.8)	0.138
Fluid npLcn2	36.2 (26.9–38.8)	56.3 (31.3–68.7)	0.029

LVEF, left ventricular ejection fraction; npLcn2, non-polyaminated lipocalin-2; pLcn2, polyaminated lipocalin-2.

^aData are shown as median (interquartile range) values.

with npLcn2. Moreover, no positive staining for pLcn2 was found in cells of the paracardial adipose tissue and the mesothelial cell layer.

Based on the distribution of npLcn2 protein, samples were sorted into those with no or less than five positively stained cells (Group I, $n = 9$), or more than five positively stained cells (mainly leucocytes) (Group II, $n = 11$), and those with the positive staining widely distributed in leucocytes, adipocytes, and mesothelial cells (Group III, $n = 12$). Compared with those in Groups I and II, patients in Group III exhibited the highest npLcn2 levels in both plasma and pericardial fluid samples. Among the 10 subjects with LVEF equal or below 50%, seven were from Group III and showed massive expression and distribution of npLcn2 in the pericardium. Compared with

Group I, plasma TC and creatinine concentrations were significantly elevated in patients from both Groups II and III (Figure 3). From Group I to Group III, the plasma HDL and adiponectin levels progressively decreased, whereas the circulating LDL and HbA1c levels gradually increased (Figure S5). The pericardial fluid contents of hsCRP were the highest in samples from Group III (1.7 mg/mL) when compared with those in patients of the other two groups (0.9 and 1.1 mg/mL in Groups I and II, respectively).

Protein uptake of lipocalin-2 by neutrophils

As shown in Figure 3, npLcn2 staining was not found in the mesothelial cells or adipocytes of the pericardium in patient samples of Groups I and II but mainly present in cells within blood or lymphatic vessels. When patients exhibited two or more components of the metabolic syndrome, npLcn2 was detected in leucocytes of samples derived from both Groups II and III. In addition, the latter group displayed excessive expression and accumulation of npLcn2 in the mesothelial cells and adipocytes of the pericardium (Figure 3 and Figure S5). The results indicated a scavenger role of certain leucocytes in eliminating the locally produced npLcn2.

To test the above hypothesis, cellular experiment was performed to investigate the interactions between mesothelial

Figure 2 Comparison of lipocalin-2 concentrations in plasma and pericardial fluid samples from Danish patients stratified by the number of the components of metabolic syndrome. Both polyaminated lipocalin-2 (pLcn2; left) and non-polyaminated lipocalin-2 (npLcn2; right) levels were measured and compared for the plasma (top) and pericardial fluid (bottom) samples of Danish patients. * $P < 0.05$ vs. the group with zero component of metabolic syndrome ($n = 8$ –15).





Figure 3 Expression and distribution of non-polyaminated lipocalin-2 (npLcn2) protein in the pericardium tissue biopsies collected from Danish patients during cardiothoracic surgery. (A) Immunohistochemical staining was performed for pericardium tissue sections using polyclonal antibodies against npLcn2. (B) Samples were stratified by the pattern of npLcn2 expression and distribution in pericardium tissue sections. Note that the average left ventricular ejection fraction (LVEF) of patients in Group III was significantly lower than that of Groups I and II. Arrows indicate the positive staining of npLcn2. A = adipocytes, M = mesothelial cells, and L = leucocytes. Magnification, $\times 200$. (C) Based on the number of positively stained cells and the distribution pattern, samples were separated into three groups for comparison of their lipocalin-2, total cholesterol, and plasma creatinine levels. $*P < 0.05$ ($n = 9-12$).



cells and neutrophils. Human lipocalin-2 protein was present in the mesothelial Met-5A cells (Figure S6A). When cultured in the control media, no positive signals for lipocalin-2 were detected in neutrophils isolated from the bone marrow of mice without lipocalin-2. However, positive staining of lipocalin-2 was detected in ~20% neutrophils cultured in the conditioned media from human primary mesothelial cells (Figure S6B). To further confirm that neutrophils were able to take up exogenous lipocalin-2, mice with selective depletion of LCN2 gene in the myeloid lineage (Lys-LKO) were established (Figure S6C). The mRNA expression of LCN2 was absent in neutrophils isolated from Lys-LKO. However, the protein presence of lipocalin-2 was readily detectable in neutrophils isolated from both Lys-LKO and the control Lcn2-floxed mice (Figure S6D).

Discussion

Human and murine lipocalin-2 are modified by polyamination.⁹ The amount of polyamines attached to lipocalin-2 determines its circulating half-life and biological activity. Using antibodies specifically recognizing pLcn2 and npLcn2, respectively, the present study demonstrated that endogenous lipocalin-2 exists as both the polyaminated and non-polyaminated forms in human samples including serum,

plasma, urine, pericardial fluid, and the parietal pericardium. Compared with those of pLcn2, the expression and distribution of npLcn2 are more sensitively correlated with the risk factors for cardio-renal metabolic syndrome and highly up-regulated in the parietal pericardium of patients with heart failure. The study provided the first evidence to support the existence of npLcn2 in human biofluid and tissue samples. Compared with pLcn2, npLcn2 exhibited different patterns of expression and distribution and was more sensitively correlated with various anthropometric and clinical parameters of cardiometabolic renal syndrome. The levels of npLcn2 and the ratio of npLcn2 vs. pLcn2 could be applied to stratify obese subjects with or without metabolic syndrome, or human patients having or not a severe condition of heart/renal failure. The study also supported npLcn2 as a promising drug target for therapeutic development in obesity-associated medical complications.

Under physiological conditions, lipocalin-2 is undetectable or present at very low levels in the heart and kidney. In response to injury, infection, or other pathological conditions, increased lipocalin-2 expression is found in kidney, heart, liver, colon, and breast tissues.²⁵ The rapid rise of urinary lipocalin-2 is an early biomarker for acute renal failure, which occurs in up to 40% of adults after cardiac surgery and complicates up to 10% of cardiac surgical procedures in infants and children with congenital heart disease.^{26,27} Only a few studies have reported reference ranges of circulating and urinary

lipocalin-2 levels in normal subjects.^{27–29} To the best of the authors' knowledge, the present study is the first to report urinary lipocalin-2 levels in a healthy cohort of subjects and a non-hospitalized Chinese population. Urinary npLcn2 levels are significantly augmented in subjects with metabolic syndrome. The results also demonstrate a significantly increased urinary lipocalin-2 but decreased circulating lipocalin-2 in female subjects, when compared with male subjects. It is not known whether or not the source of lipocalin-2 production contributes to the gender differences.

Circulating lipocalin-2 is filtered in the kidney by the glomeruli, while the protein is captured by the proximal tubular epithelial cells.^{30,31} Thus, when injected into the circulation, exogenous lipocalin-2 is enriched in the proximal tubule but does not appear in the urine in large quantities.²⁶ This is in line with the present findings that serum and urinary lipocalin-2 levels are not significantly correlated with each other in healthy human subjects. Lipocalin-2 in urine represents a collection of different pools of the protein, including those freely filtered into the tubular space, released from injured tubular cells, and locally expressed and excreted.^{32,33} In response to ischemic or nephrotoxic injury, lipocalin-2 mRNA is expressed in the loop of Henle and the collecting ducts.³⁴ This locally synthesized lipocalin-2 is unlikely to be introduced back into the circulation but rather excreted into the urine.³⁵ The plasma lipocalin-2 concentration increases progressively with the reduction of glomerular filtration rate (GFR).²⁷ Owing to impaired removal of lipocalin-2 from the circulation, urinary lipocalin-2 may represent mainly protein that is expressed/produced locally.³⁶ Thus, measurements of lipocalin-2 from different sources have important clinical implications regarding disease progression and treatment strategies. It would be interesting to test whether or not npLcn2 in urine is produced mainly by the injured tubular/ductal cells, whereas pLcn2 is derived from the circulation via glomerular filtration, or vice versa.

Lipocalin-2 represents an important link between renal and cardiovascular dysfunctions.^{37,38} It is a stronger predictor for mortality than GFR and cystatin C in patients with heart failure.^{39–41} Urinary lipocalin-2 in patients without kidney injury decreases rapidly after cardiac surgery.⁴² Both urinary and plasma lipocalin-2 levels are increased in patients with cardio-renal syndrome types 1 and 2.^{6,43–46} These data collectively suggest that high lipocalin-2 levels do not merely reflect impaired renal function but may be related to the cardiac abnormality per se. In fact, urinary and plasma lipocalin-2 levels are positively associated with increased N-terminal pro-brain natriuretic peptide, the New York Heart Association class, and the left ventricular internal end-diastolic dimension in patients with chronic heart failure.^{36,47} Plasma lipocalin-2 levels correlate with heart failure severity and predict major adverse cardiovascular events in critically ill patients.⁴⁸ The present study demonstrates that npLcn2 represents a more specific marker for cardio-renal metabolic syndrome. In healthy

subjects, plasma npLcn2 levels are positively correlated with heart rate, independent of age, gender, smoking, and BMI. In cardiothoracic surgery patients, plasma and pericardial fluid npLcn2 are elevated to a much higher level than pLcn2 and positively correlated with the risk biomarkers such as hsCRP. Importantly, npLcn2 is overexpressed in the pericardium of patients with reduced LVEF, an indicator of heart failure. This group (III) of patients have higher plasma levels of LDL, TC, HbA1c, and creatinine and lower plasma levels of HDL and adiponectin than Groups I and II.

The pericardium is a fibrous-serosal cavity surrounding the heart that contains a small amount of fluid. A monolayer of flattened, squamous-like mesothelial cells lines the inner surface of the pericardial cavity and plays a role in absorbing the pericardial fluid for drainage through the lymphatic capillary bed. In addition to anatomic isolation and lubrication of the moving surfaces of the heart, the normal pericardium prevents cardiac hypertrophy in pressure overload conditions and preserves the negative endothoracic pressure for atrial filling.⁴⁹ A significant amount of npLcn2 is present in the pericardial fluid of patients with heart failure. Histological studies confirmed the expression of npLcn2 protein in the mesothelial cells and the paracardial adipocytes of these patients' biopsies. In addition, about two-thirds of the tissue sections contained npLcn2-positive blood cells (leucocytes), which are mainly located within venules or lymphatic vessels but not arterioles. Although pLcn2 and npLcn2 were both detectable in the leucocytes, their patterns of distribution differed significantly as judged from the staining of adjacent tissue sections. The findings suggest that leucocytes such as neutrophils or macrophages act as scavengers to clear npLcn2 protein from the pericardium. During this process, npLcn2 is polyaminated inside the leucocytes and stored in the form of pLcn2 for subsequent drainage and elimination. Thus, excessive production and accumulation of npLcn2 in the pericardium not only determine systemic lipocalin-2 levels but also play a pathogenic role in the development of cardiac diseases. Measurement of different forms of lipocalin-2, especially npLcn2, could be clinically important for early detection, risk stratification, and outcome prediction of patients with cardio-renal abnormalities.

The present study has some limitations, including a relatively low subject number, different pathophysiological mechanisms, lack of longitudinal assessment, absence of information concerning leucocyte counts or renal function in the studied patients, and its observational nature. As a retrospective single-centre analysis, selection bias may not be excluded entirely. Additional research is needed in larger and more diverse patient populations to further evaluate and validate the present findings. Despite these limitations, the present findings suggest that npLcn2 is a novel and sensitive biomarker for cardiometabolic risk and cardio-renal function assessment. Assays used in the present study are

able to differentiate the pathophysiological expression of pLcn2 and npLcn2 in human samples.

Conflict of interest

None.

Funding

Seeding Funds for Basic Research of the University of Hong Kong, Research Grant Council (17121714, HKU780613M, and HKU763312M); Collaborative Research Funds (C7055-14G) of Hong Kong; National Basic Research Program of China (973 Program 2015CB553603).

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article.

Figure S1. Polyclonal antibodies against wild type human lipocalin-2 or C87A selectively recognize different species of lipocalin-2. Equal amount of purified wild type human lipocalin-2 and C87A mutant were mixed in one test tube and then incubated with 2 μ g anti-human lipocalin-2 or anti-C87A antibody for 6 hours at 4°C. Subsequently, 70 μ L of protein A sepharose bead slurry was added for immunoprecipitation. The precipitated proteins were separated in 15% SDS-PAGE and detected with anti-pLcn2 antibody.

Figure S2. Detection of polyaminated and non-polyaminated lipocalin-2 in human urine samples. A, The concentrated urine samples were separated by SDS-PAGE (15 μ L/lane) and then subjected to Western blotting detection by polyclonal antibodies against pLcn2 (anti-pLcn2) or npLcn2 (anti-npLcn2). B, Immunoprecipitation (ip) was performed in two of the nine urine samples using anti-pLcn2 and anti-npLcn2, respectively.

Polyamines attached to the precipitated lipocalin-2 protein were detected using antibodies recognizing spermidine.

Figure S3. Frequency distribution of serum (top) and urine (bottom) lipocalin-2 concentrations for samples of the Hong Kong healthy volunteer cohort. The 95th and 75th percentile values are indicated for both pLcn2 (left) and npLcn2 (right) levels.

Figure S4. Representative images of tissue sections stained by polyclonal antibodies against pLcn2 (left) or npLcn2 (right). The parietal pericardium tissue biopsies were collected from Danish patients during cardiothoracic surgery and subsequently processed for immunohistological analyses. Arrows indicate the different types of cells with pLcn2 or npLcn2 positive staining (brown color). A=Adipocytes, M=Mesothelial cells, L=Leukocytes.

Figure S5. Comparison of cardiometabolic parameters among the three groups of samples. Based on the number of positively stained cells and the distribution pattern of npLcn2 (Figure 3), samples from Danish patient cohort were separated into three groups for comparison of their HDL, LDL, HbA1c and plasma adiponectin levels. ($n = 9-12$).

Figure S6. Neutrophil uptake of lipocalin-2 protein. A, Protein expression of human lipocalin-2 (arrow head) was detected by Western blotting in the cell lysates (10 μ g total protein) collected from Met-5A cultures. Purified pLcn2 protein (2 μ g/lane) was loaded at the left for comparison. B, Neutrophils isolated from mice without lipocalin-2 were incubated with the control (top) or conditioned (bottom) media collected from human primary mesothelial cell cultures. Immunofluorescence was performed to detect the protein content of human lipocalin-2 (red) inside the neutrophils. Nuclei were counterstained by DAPI (blue). Magnification, 400 \times . C, Genotyping was performed using the three sets of primers to identify Lcn2-floxed and Lys-LKO mice. Mice with a positive product of Primer 1 and 2 were selected as Lys-LKO mice. The control Lys-floxed mice had only the positive band of 319 bp amplified by Primer 2. D, Neutrophils isolated from Lcn2-floxed and Lys-KO mice were subjected to quantitative PCR analysis to detect mRNA expression of lipocalin-2 (top) or Western blotting (bottom) to detect the presence of lipocalin-2 protein.

References

1. Flower DR. The lipocalin protein family: structure and function. *Biochem J* 1996; **318**(Pt 1): 1–14.
2. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. *J Biol Chem* 1993; **268**: 10425–10432.
3. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestering iron. *Nature* 2004; **432**: 917–921.
4. Liu JT, Song E, Xu A, Berger T, Mak TW, Tse HF, Law IK, Huang B, Liang Y, Vanhoutte PM, Wang Y. Lipocalin-2 deficiency prevents endothelial dysfunction associated with dietary obesity: role of cytochrome P450 2C inhibition. *Br J Pharmacol* 2012; **165**: 520–531.
5. Wang Y. Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2. *Br J Pharmacol* 2012; **165**: 603–621.
6. Yndestad A, Landro L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Froland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Oie E, Gullestad L, Aukrust P. Increased systemic and

- myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. *Eur Heart J* 2009; **30**: 1229–1236.
7. Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Berger T, Mak TW, Knebelmann B, Friedlander G, Barasch J, Terzi F. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. *J Clin Invest* 2010; **120**: 4065–4076.
 8. Tarjus A, Martinez-Martinez E, Amador C, Latouche C, El Moghrabi S, Berger T, Mak TW, Fay R, Farman N, Rossignol P, Zannad F, Lopez-Andres N, Jaisser F. Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids. *Hypertension* 2015; **66**: 158–166.
 9. Song E, Fan P, Huang B, Deng HB, Cheung BM, Feletou M, Vilaine JP, Villeneuve N, Xu A, Vanhoutte PM, Wang Y. Deamidated lipocalin-2 induces endothelial dysfunction and hypertension in dietary obese mice. *J Am Heart Assoc* 2014; **3**: e000837.
 10. Law IK, Xu A, Lam KS, Berger T, Mak TW, Vanhoutte PM, Liu JT, Sweeney G, Zhou M, Yang B, Wang Y. Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity. *Diabetes* 2010; **59**: 872–882.
 11. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, Chow WS, Wat NM, Xu JY, Hoo RL, Xu A. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. *Clin Chem* 2007; **53**: 34–41.
 12. Yan QW, Yang Q, Mody N, Graham TE, Hsu CH, Xu Z, Houstis NE, Kahn BB, Rosen ED. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. *Diabetes* 2007; **56**: 2533–2540.
 13. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. *Obes Res* 2001; **9**(Suppl 4): 228S–233S.
 14. Elie AG, Jensen PS, Nissen KD, Geraets IM, Xu A, Song E, Hansen ML, Irmukhamedov A, Rasmussen LM, Wang Y, De Mey JG. Adipokine imbalance in the pericardial cavity of cardiac and vascular disease patients. *PLoS One* 2016; **11**: e0154693.
 15. Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, Chisholm DJ, George J. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. *Hepatology* 2009; **49**: 1926–1934.
 16. Zhou M, Bao Y, Lu J, Zhou J, Jia W. Serum A-FABP is increased and closely associated with elevated NT-proBNP levels in type 2 diabetic patients treated with rosiglitazone. *PLoS One* 2011; **6**: e27032.
 17. Xiao Y, Xu A, Law LS, Chen C, Li H, Li X, Yang L, Liu S, Zhou Z, Lam KS. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. *J Clin Endocrinol Metab* 2012; **97**: E54–E58.
 18. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, Itoh N, Wang Y, Bornstein SR, Xu A, Li X. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. *Cell Metab* 2013; **17**: 779–789.
 19. Xiao Y, Xu A, Hui X, Zhou P, Li X, Zhong H, Tang W, Huang G, Zhou Z. Circulating lipocalin-2 and retinol-binding protein 4 are associated with intima-media thickness and subclinical atherosclerosis in patients with type 2 diabetes. *PLoS One* 2013; **8**: e66607.
 20. Yu H, Xia F, Lam KS, Wang Y, Bao Y, Zhang J, Gu Y, Zhou P, Lu J, Jia W, Xu A. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. *Clin Chem* 2011; **57**: 691–700.
 21. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ, Lam KS. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. *J Biol Chem* 2005; **280**: 18073–18080.
 22. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. *Clin Chem* 2006; **52**: 405–413.
 23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002; **106**: 3143–3421.
 24. Bonventre JV. Kidney injury molecule-1: a translational journey. *Trans Am Clin Climatol Assoc* 2014; **125**: 293–299.
 25. Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. *Biochim Biophys Acta* 2012; **1826**: 129–169.
 26. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D'Agati V, Devarajan P, Barasch J. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. *J Clin Invest* 2005; **115**: 610–621.
 27. Donadio C. Effect of glomerular filtration rate impairment on diagnostic performance of neutrophil gelatinase-associated lipocalin and B-type natriuretic peptide as markers of acute cardiac and renal failure in chronic kidney disease patients. *Crit Care* 2014; **18**: R39.
 28. Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. *Clin Chem Lab Med* 2012; **50**: 1505–1517.
 29. Cullen MR, Murray PT, Fitzgibbon MC. Establishment of a reference interval for urinary neutrophil gelatinase-associated lipocalin. *Ann Clin Biochem* 2012; **49**(Pt 2): 190–193.
 30. Le Cabec V, Calafat J, Borregaard N. Sorting of the specific granule protein, NGAL, during granulocytic maturation of HL-60 cells. *Blood* 1997; **89**: 2113–2121.
 31. Hochmeister S, Engel O, Adzemovic MZ, Pekar T, Kendlbacher P, Zeitelhofer M, Haindl M, Meisel A, Fazekas F, Seifert-Held T. Lipocalin-2 as an infection-related biomarker to predict clinical outcome in ischemic stroke. *PLoS One* 2016; **11**: e0154797.
 32. Waikar SS, Bonventre JV. Biomarkers for the diagnosis of acute kidney injury. *Nephron Clin Pract* 2008; **109**: c192–c197.
 33. Pawluczcyk IZ, Furness PN, Harris KP. Macrophage-induced rat mesangial cell expression of the 24p3-like protein alpha-2-microglobulin-related protein. *Biochim Biophys Acta* 2003; **1645**: 218–227.
 34. Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, Grenet O, Pantano S, Moulin P, Wahl D, Mahl A, End P, Staedtler F, Legay F, Carl K, Laurie C, Chibout SD, Vonderscher J, Maurer G. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. *Nat Biotechnol* 2010; **28**: 463–469.
 35. Schmidt-Ott KM, Mori K, Kalandadze A, Li JY, Paragas N, Nicholas T, Devarajan P, Barasch J. Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia. *Curr Opin Nephrol Hypertens* 2006; **15**: 442–449.
 36. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. *Eur J Heart Fail* 2008; **10**: 997–1000.
 37. Bolognani D, Coppolino G, Lacquaniti A, Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. *Eur J Clin Invest* 2010; **40**: 273–276.
 38. Iqbal N, Alim KS, Aramin H, Iqbal F, Green E, Higginbotham E, Maisel AS. Novel biomarkers for heart failure. *Expert Rev Cardiovasc Ther* 2013; **11**: 1155–1169.
 39. van Deursen VM, Damman K, Voors AA, van der Wal MH, Jaarsma T, van Veldhuisen DJ, Hillege HL. Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. *Circ Heart Fail* 2014; **7**: 35–42.

40. Minana G, Rumiz E, Palau P, Valero E, Bodi V, Nunez E, Sanchis J, Nunez J. Plasma neutrophil gelatinase-associated lipocalin and long-term mortality in patients with acute heart failure and normal renal function. *Int J Cardiol* 2016; **214**: 51–53.
41. Alvelos M, Lourenco P, Dias C, Amorim M, Rema J, Leite AB, Guimaraes JT, Almeida P, Bettencourt P. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. *Int J Cardiol* 2013; **165**: 51–55.
42. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, Lee HT. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. *Anesthesiology* 2006; **105**: 485–491.
43. Palazzuoli A, Ruocco G, Beltrami M, Franci B, Pellegrini M, Lucani B, Nuti R, Ronco C. Admission plasma neutrophil gelatinase associated lipocalin (NGAL) predicts worsening renal function during hospitalization and post discharge outcome in patients with acute heart failure. *Acute Card Care* 2014; **16**: 93–101.
44. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. *Kidney Int* 2007; **71**: 967–970.
45. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis* 2009; **54**: 1012–1024.
46. Alvelos M, Pimentel R, Pinho E, Gomes A, Lourenco P, Teles MJ, Almeida P, Guimaraes JT, Bettencourt P. Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward. *Clin J Am Soc Nephrol* 2011; **6**: 476–481.
47. Poniatowski B, Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease. *Kidney Blood Press Res* 2009; **32**: 77–80.
48. Katagiri M, Takahashi M, Doi K, Myojo M, Kiyosue A, Ando J, Hirata Y, Komuro I. Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease. *Heart Vessels* 2016; **31**: 1595–1602.
49. Mutsaers SE, Birnie K, Lansley S, Herrick SE, Lim CB, Prele CM. Mesothelial cells in tissue repair and fibrosis. *Front Pharmacol* 2015; **6**: 113.